BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38317364)

  • 1. [Analysis of efficacy and safety of daratumumab-containing regimen in relapsed and refractory multiple myeloma patients].
    Yu QR; Zhou X; Wu HY; Hao LM; Li XM; Zhong YP
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):521-525. PubMed ID: 38317364
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
    Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
    Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
    [No Abstract]   [Full Text] [Related]  

  • 3. [The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment].
    Yin LL; Shen YL; Min FL; Gu WY; Wang Y; Qi KM; Li ZY; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):141-147. PubMed ID: 36765491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
    Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
    Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
    Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
    Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 11. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
    Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
    N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
    Sunami K; Murakami H; Tagashira H; Ueda H; Moriyama T; Ishikawa T; Yoshioka T; Makita M
    Int J Clin Oncol; 2020 Dec; 25(12):2151-2157. PubMed ID: 32715356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
    Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
    Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 18. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
    Harvanová Ľ; Štulajterová V; Guman T; Ladická M; Hlebašková M; Chudej J; Šimek M; Štecová N; Flochová E; Kubala J; Simančíková I; Drgoňa Ľ; Vranovský A; Wild A; Mistrík M; Bátorová A
    Neoplasma; 2021 May; 68(3):626-630. PubMed ID: 33567854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.